Introduction
What treatments are used for Acute respiratory distress syndrome? Management centers on treating the cause of lung injury, supporting oxygenation and ventilation, and limiting further damage to the delicate alveolar-capillary membrane. Acute respiratory distress syndrome, or ARDS, is not a single disease but a severe inflammatory pattern of lung failure that can follow sepsis, pneumonia, aspiration, trauma, or other major insults. The main treatment approaches include supplemental oxygen, mechanical ventilation with lung-protective settings, prone positioning, fluid management, and treatment of the underlying trigger such as infection or shock. These therapies aim to correct impaired gas exchange, reduce ventilator-induced injury, control systemic inflammation, and preserve organ function while the lungs recover.
Understanding the Treatment Goals
The central problem in ARDS is diffuse inflammation of the lungs that damages the alveolar lining and the surrounding capillaries. This injury increases membrane permeability, allowing protein-rich fluid to flood the air sacs and reduce lung compliance. Oxygen cannot move efficiently into the bloodstream, and carbon dioxide removal may also become impaired. Treatment is therefore directed at several linked goals: improving oxygen delivery, reducing the work of breathing, preventing collapse and overdistension of injured alveoli, and treating the condition that triggered the inflammatory cascade.
These goals guide therapy because the immediate threat in ARDS is not only low oxygen levels but also progressive structural damage from both the disease process and the interventions used to support breathing. A treatment plan must balance the need for adequate gas exchange against the risk of adding further injury through high airway pressures, excessive oxygen exposure, or fluid overload. In practice, clinicians select therapies that support the lungs while allowing time for the inflammatory process to resolve.
Common Medical Treatments
Supplemental oxygen is usually the first step in treatment. It increases the fraction of inspired oxygen, raising the pressure gradient for diffusion across the damaged alveolar membrane. This improves arterial oxygen content even when part of the lung is poorly ventilated. Oxygen can be delivered by nasal cannula, face mask, high-flow systems, or through a ventilator if noninvasive methods are insufficient. Its primary target is hypoxemia, the hallmark physiologic abnormality in ARDS.
When oxygen alone cannot maintain adequate gas exchange, invasive mechanical ventilation is used. The key principle is lung-protective ventilation. Rather than forcing large volumes of air into stiff, inflamed lungs, the ventilator delivers smaller tidal volumes and limits the pressure applied to the airways. This reduces volutrauma and barotrauma, which occur when fragile alveoli are stretched or ruptured by excessive mechanical stress. Lower tidal volumes also help prevent repeated opening and closing of collapsed alveoli, a process called atelectrauma, which worsens inflammation.
Positive end-expiratory pressure, or PEEP, is another core component of ventilator management. PEEP keeps alveoli partially inflated at the end of exhalation, preventing collapse and increasing the amount of lung available for gas exchange. Physiologically, this improves functional residual capacity and reduces shunt, the condition in which blood passes through the lungs without being adequately oxygenated. Appropriate PEEP can also stabilize fluid-filled alveoli and reduce the cyclic stress of repetitive collapse and reinflation.
In some patients, sedation is used to improve synchrony with the ventilator and reduce oxygen demand. When the work of breathing is extreme, muscle relaxation may be required briefly. These drugs do not treat the lung injury itself, but they make controlled ventilation possible and reduce the risk that patient-ventilator dyssynchrony will produce injurious airway pressures. By decreasing unnecessary respiratory effort, sedation can help maintain stable oxygenation and ventilation while minimizing additional mechanical stress.
Treatment of the underlying cause is equally important. If sepsis is driving ARDS, antibiotics and source control address the infectious trigger that perpetuates inflammation and capillary leak. If aspiration, pancreatitis, trauma, or transfusion reaction is responsible, management targets the initiating process. These treatments work by removing or suppressing the stimulus for the inflammatory response, which can help limit ongoing lung damage and support recovery.
In selected cases, medications may be used for specific complications or contributing factors rather than for ARDS itself. Vasopressors support blood pressure in septic shock and improve perfusion of vital organs. Antibiotics target bacterial pneumonia or bloodstream infection. Diuretics may be used when excess fluid is worsening pulmonary edema, provided blood pressure and organ perfusion can be maintained. These therapies influence the physiologic environment in which the lungs are functioning, even though they do not directly reverse alveolar damage.
Procedures or Interventions
One of the most effective nonpharmacologic interventions in moderate to severe ARDS is prone positioning. Turning the patient onto the abdomen redistributes transpulmonary pressure and improves ventilation-perfusion matching. In the supine position, the posterior lung regions, which receive substantial blood flow, are often compressed by the heart and abdominal contents and become poorly ventilated. Proning helps reopen these dependent regions, reduce shunt, and improve oxygenation. It also may lower stress on overinflated anterior lung units, distributing mechanical forces more evenly.
In severe cases, extracorporeal membrane oxygenation, or ECMO, may be used. ECMO removes blood from the body, oxygenates it outside the lungs, and returns it to the circulation. This bypasses the injured lungs and permits very low ventilator settings, reducing the risk of further mechanical damage. ECMO does not heal the lungs directly; rather, it temporarily replaces gas exchange so that time can pass for the inflammatory injury to resolve. It is reserved for cases in which conventional ventilation and other measures fail to provide adequate oxygenation or carbon dioxide removal.
Some patients require invasive procedures to monitor or support critical illness associated with ARDS. An arterial line may be placed to measure blood pressure continuously and obtain frequent blood gas samples, which reflect oxygenation, ventilation, and acid-base status. Central venous access may be needed for vasopressor infusion, fluid management, or difficult venous access. These interventions do not treat the lung pathology itself, but they allow precise adjustment of therapy in a condition where small physiologic changes can have major effects.
Supportive or Long-Term Management Approaches
Fluid management plays a major role in ARDS support. Because the alveolar-capillary barrier is leaky, excess intravascular volume can worsen pulmonary edema and impair oxygen exchange. A conservative fluid strategy reduces hydrostatic pressure in the pulmonary circulation and limits the amount of fluid that moves into the injured interstitium and alveoli. This approach works best after initial resuscitation of shock has been completed, when avoiding additional fluid can help restore a more favorable balance between circulating volume and lung edema.
Nutrition support is also important because severe critical illness increases metabolic demand and can lead to catabolism. Enteral feeding helps preserve gut integrity and provides energy for tissue repair. Although nutrition does not reverse ARDS directly, it supports respiratory muscle function, immune activity, and recovery from critical illness. Physical rehabilitation may become important during recovery, since prolonged ventilation and intensive care often lead to profound weakness that limits eventual return to normal function.
Monitoring and follow-up are part of ARDS management because the condition can evolve rapidly. Repeated assessment of oxygenation, ventilator parameters, blood gases, fluid balance, and organ function helps guide therapy as lung compliance and gas exchange change over time. After the acute phase, some patients need follow-up for persistent exercise limitation, muscle weakness, or post-intensive care lung impairment. In that setting, management focuses on functional recovery and detection of complications such as fibrosis, although many patients improve substantially as inflammation resolves.
Factors That Influence Treatment Choices
Treatment varies with severity. Mild ARDS may respond to supplemental oxygen and close monitoring, while severe ARDS often requires mechanical ventilation, prone positioning, and sometimes ECMO. Oxygenation status, respiratory mechanics, and the extent of organ failure all influence escalation. The more severe the alveolar injury and shunt, the more likely it is that advanced interventions will be needed to maintain oxygen delivery while preventing further injury.
The stage of illness also matters. Early ARDS is dominated by active inflammation, capillary leak, and rapidly changing respiratory mechanics. In this phase, the priority is supportive care and treatment of the trigger. Later, when inflammation subsides, residual atelectasis, fluid balance, and weakness may become more prominent. As the physiologic pattern changes, treatment is adjusted to match the dominant problem.
Age, baseline health, and related medical conditions influence both tolerance and risk. A patient with chronic heart failure may be especially sensitive to fluid administration, while someone with chronic obstructive pulmonary disease may have different ventilatory requirements because of air trapping. Immunosuppression, kidney injury, or liver disease can affect drug selection and the ability to recover from critical illness. These factors change the balance between aggressive respiratory support and the risk of complications.
Response to prior treatment also guides decisions. If oxygenation improves with PEEP, prone positioning, or fluid removal, the same strategy may be continued. If oxygenation remains poor despite optimized ventilation, escalation to ECMO or other rescue approaches may be considered. Treatment is therefore dynamic, based on how the lungs and other organs respond to ongoing support rather than on a fixed protocol alone.
Potential Risks or Limitations of Treatment
Many ARDS treatments carry risks because they act on fragile lungs or critically ill patients. Mechanical ventilation can injure the lungs if pressures or volumes are too high, causing barotrauma, volutrauma, or further inflammatory injury. Even when carefully set, ventilation cannot repair the underlying permeability defect; it only supports gas exchange while recovery occurs. This is why lung-protective settings are emphasized.
High oxygen concentrations can also have limitations. Prolonged exposure to very high oxygen levels may contribute to oxygen toxicity through oxidative injury, especially if used without adequate ventilation strategies. Clinicians therefore aim to use the lowest oxygen concentration that maintains acceptable blood oxygen levels. Prone positioning improves oxygenation in many patients, but it requires staffing, careful coordination, and attention to pressure injury or accidental removal of lines and tubes.
Fluid restriction may improve pulmonary edema but can reduce organ perfusion if taken too far. The challenge is that ARDS often occurs in the setting of sepsis or shock, where some fluid resuscitation is initially necessary. ECMO can be lifesaving, but it is resource-intensive and carries risks of bleeding, thrombosis, infection, and vascular complications. The need for anticoagulation during extracorporeal support increases complexity, especially in patients with trauma or other bleeding risks.
Finally, no treatment rapidly reverses the structural damage of ARDS. Recovery depends on the lung’s ability to repair the injured alveolar-capillary barrier. Supportive treatment buys time for that process, but the timeline can be prolonged, and some patients develop persistent weakness or residual lung impairment after the acute illness. The main limitation of therapy is therefore biological: current treatment can stabilize physiology and reduce secondary injury, but it cannot instantly restore the normal architecture of the lung.
Conclusion
Acute respiratory distress syndrome is treated by combining respiratory support, treatment of the underlying cause, and careful control of the physiologic conditions that worsen lung injury. Supplemental oxygen, lung-protective mechanical ventilation, positive end-expiratory pressure, prone positioning, fluid management, and in severe cases ECMO all work by improving oxygenation while minimizing further damage to the injured alveoli and capillaries. Other measures, such as antibiotics, vasopressors, sedation, and nutrition support, address the disease trigger and the systemic effects of critical illness. The overall strategy is not to cure ARDS directly, but to preserve gas exchange, prevent complications, and support the lungs until the inflammatory injury resolves and normal function can recover.